Erik A. Klein, MD, presented “Overview of MCED – Performance and Impact on Prostate Cancer” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Klein, Erik A. “Overview of MCED – Performance and Impact on Prostate Cancer.” October 8, 2024. Accessed Dec 2024. https://grandroundsinurology.com/overview-of-mced-performance-and-impact-on-prostate-cancer/
Overview of MCED – Performance and Impact on Prostate Cancer – Summary
Erik A. Klein, MD, highlights data on GRAIL’s multi-cancer early detection (MCED) test, focusing on its performance in identifying prostate cancer. The test detects cancer signals in circulating cell-free DNA from a single blood draw using next-generation sequencing and targeted methylation analysis. This approach aims to complement standard screening methods like PSA tests, addressing the limitations of overdiagnosis associated with PSA alone.
In this 11-minute presentation, Dr. Klein reviews the CCGA and the Pathfinder studies, demonstrating the test’s ability to detect high-grade prostate cancers while minimizing the detection of low-grade or indolent cases. He analyzes data from both studies, indicating that the MCED test detects high-grade and advanced-stage prostate cancers.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Eric A. Klein, MD is the Andrew C. Novick Distinguished Chair of the Glickman Urological and Kidney Institute and Professor of Surgery in the Lerner College of Medicine of the Cleveland Clinic. He was a cum laude graduate of the University of Pittsburgh School of Medicine and subsequently completed residency training in Urology at the Cleveland Clinic and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. He served as President of the Society of Urologic Oncology from 2009 - 2011. Dr. Klein’s clinical and research interests cover all stages of prostate cancer with a focus on genomics and clinical trials. He has served as Chairman of the Localized Prostate Cancer Committee of the Southwest Oncology Group and was the National Study Coordinator for the NCI-sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein has contributed more than 600 papers to the scientific literature, authored or edited eight books on urologic malignancies, and serves as the Editor-in-Chief of Urology. He has delivered more than 200 invited scientific lectures, including 13 named lectureships, and has served as a Visiting Professor at more than 60 institutions around the world. Dr. Klein was awarded the F. Mason Sones Innovation Award by the Cleveland Clinic in 2009, The Joe V. Meigs Award by the Society of Pelvic Surgeons in 2013 and 2015, was named the Kidney Foundation of Ohio’s Person of the Year in 2017, and has received five career achievement awards including a 2014 Presidential Citation from the American Urological Association, the 2014 Huggins Medal from the Society of Urologic Oncology, the 2015 Philip S. Hench Award from the University of Pittsburgh School of Medicine, the 2020 SUO Medal from the Society of Urologic Oncology, and the 2020 Richard D. Williams, MD Prostate Cancer Research Excellence Award from the Urology Care Foundation.
